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In Brief
Fibroblastic reticular cells control matrix
production for lymph node conduit
function. Martinez et al. show that matrix
production is reduced and conduit flow is
altered during lymph node expansion.
Matrix deposition by fibroblastic reticular
cells is controlled by CLEC-2/podoplanin
signaling and directed unilaterally into
conduit structures by LL5-b-tethered
microtubules.
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Lymph nodes (LNs) act as filters, constantly sam-
pling peripheral cues. This is facilitated by the
conduit network, a tubular structure of aligned
extracellular matrix (ECM) fibrils ensheathed by
fibroblastic reticular cells (FRCs). LNs undergo rapid
3- to 5-fold expansion during adaptive immune re-
sponses, but these ECM-rich structures are not
permanently damaged. Whether conduit flow or
filtering function is affected during LN expansion is
unknown. Here, we show that conduits are partially
disrupted during acute LN expansion, but FRC-FRC
contacts remain connected. We reveal that polarized
FRCs deposit ECM basolaterally using LL5-b and
that ECM production is regulated at transcriptional
and secretory levels by the C-type lectin CLEC-2,
expressed by dendritic cells. Inflamed LNs maintain
conduit size exclusion, and flow is disrupted but per-
sists, indicating the robustness of this structure
despite rapid tissue expansion. We show how dy-
namic communication between peripheral tissues
and LNs provides a mechanism to prevent inflamma-
tion-induced fibrosis in lymphoid tissue.
INTRODUCTION
Lymph node (LN) functional organization is formed and main-
tained by stromal cells (Link et al., 2007). Once thought to pro-
vide only the necessary scaffolds to support the architecture of
the tissue, LN stromal cells are now recognized as key players
in immunity (Buechler and Turley, 2018). Four main populations
of stromal cells can be defined in LNs: podoplanin
(PDPN)CD31+ blood endothelial cells (BECs), PDPN+CD31+
lymphatic endothelial cells (LECs), PDPN+CD31 fibroblastic
reticular cells (FRCs), and PDPNCD31 double-negative cells
(DNs) (Novkovic et al., 2018). Among these, the FRC population
is the most abundant subset. A recent small conditional RNA2810 Cell Reports 29, 2810–2822, November 26, 2019 ª 2019 The A
This is an open access article under the CC BY license (http://creativesequencing (scRNA-seq) analysis showed that FRCs may
contain different subpopulations with specific locations and
functions (Rodda et al., 2018). FRCs form a connected 3-dimen-
sional (3D) network that spans the T cell area and interfollicular
regions of LNs. FRCs regulate the lymphocyte homeostasis
(Cremasco et al., 2014; Link et al., 2007) and induction of periph-
eral tolerance (Dubrot et al., 2014; Fletcher et al., 2010; Lee et al.,
2007). Furthermore, contraction through the FRC network also
regulates LN size during immune responses. Interactions be-
tween FRC and C-type lectin-like receptor 2-expressing
(CLEC-2+) migratory dendritic cells (DCs) transiently inhibit
PDPN-dependent actomyosin contractility during the acute
phase of the immune response (Acton et al., 2014; Astarita
et al., 2015), allowing rapid LN expansion.
LNs also function as filters for lymph-born antigens (Radtke
et al., 2015; Randolph et al., 2017). Soluble antigens reach the
LN first in a wave of draining-type diffusion ahead of a secondary
wave of migratory antigen-presenting cells. Collected by
lymphatic capillaries in the peripheral tissue, the lymph con-
verges in afferent lymphatic vessels that merge with the LN
capsule and flowswithin the subcapsular sinus (SCS). The lymph
percolates through trabecular and cortical sinuses that flow into
the LN medulla before leaving via efferent lymphatic vessels. A
sample of low-molecular-weight molecules (<70 kDa) (Gretz
et al., 2000; Nolte et al., 2003; Roozendaal et al., 2009; Sixt
et al., 2005) is permitted to flow directly through the LN paren-
chyma within an intricate tubular system called the conduit
network (Roozendaal et al., 2009). The conduit network is
composed of bundled and aligned extracellular matrix (ECM)
components enwrapped by FRCs, the main producers of ECM
in the LN (Malhotra et al., 2012; Sixt et al., 2005; Sobocinski
et al., 2010). No other fibrillar ECM structures are found in the
LN parenchyma. While we are starting to understand how the
FRC network reacts during LN expansion, it is not yet known
how the non-cellular ECM components are remodeled and
how rapid expansion of the LN may affect the function of the
conduit. In other contexts, inflammation goes hand in hand
with tissue remodeling. Injury-induced loss of the ECM is rapidly
replenished by biogenesis and crosslinking (Xue and Jackson,
2015). Chronic inflammation, as it occurs in cancers or some viraluthors.
commons.org/licenses/by/4.0/).
infections, induces deregulation of this process, leading to
fibrosis (Wynn and Ramalingam, 2012). LN fibrosis can occur
in tumor-draining LNs or in some cases of chronic viral infection
(Riedel et al., 2016; Rohner et al., 2015; Schacker et al., 2006;
Zeng et al., 2011); however, more commonly, LNs undergo a
virtually unlimited number of inflammatory episodes throughout
an individual’s lifetime and LN fibrosis does not occur. Therefore,
we hypothesized that a specific mechanism must be in place to
both confine ECM secretion exclusively to the conduit and to
avoid the accumulation of aberrant ECM during inflammation.
In this study, we focus on ECM remodeling by FRCs during LN
expansion and the interconnection between the cellular and
ECM components of the conduit network. We demonstrate
depletion and disruption of ECM components of the conduit dur-
ing acute LN expansion. We show that CLEC-2 binding to
PDPN+ FRCs modulates ECM production at both mRNA and
protein levels. Furthermore, the CLEC-2/PDPN axis regulates
polarized microtubule organization in FRCs to direct and contain
ECM deposition.
RESULTS
Extracellular Matrix Components of the Conduit Are
Reduced during Acute LN Expansion
To ask how ECM structures were maintained and remodeled dur-
ing acute LN expansion, a period of rapid tissue growth, we first
examined LN ECM structures in the steady state. Using the pas-
sive clarity technique (PACT) (Yang et al., 2014), we imaged
collagen IV in intact naive inguinal LNs (Figure 1A; Video S1).
This abundant basement membrane protein surrounded the LN
vasculature and formed an intricate 3D connected network span-
ning the whole LN parenchyma (Malhotra et al., 2012; Sixt et al.,
2005; Sobocinski et al., 2010), corresponding to the conduit
network. Electron microscopy revealed the detail of condensed
fibrillar bundles consisting of >200 collated fibers of ECMenwrap-
ped by FRCs (Figure 1B). Co-staining of the basement membrane
protein laminin and the FRC marker PDPN confirmed that in LN
parenchyma, ECM structures are found exclusively associated
with the FRC network forming the conduit (Baje´noff and Germain,
2009) and vasculature (Figure 1C).
We immunized mice with ovalbumin emulsified with incom-
plete Freund’s adjuvant (IFA/OVA) and compared the density
of collagen IV structures in LNs after 4 and 14 days (Figure 1D).
We observed that the FRC network appeared stretched but con-
nected at day 4 and that collagen IV structures were less prom-
inent. Using podoplanin staining as a mask, we quantified
collagen IV intensity exclusively within the FRC cellular network
and found a progressive loss and disruption of conduit matrix
over time in inflamed LNs (Figure 1E). We obtained similar results
for collagen I and collagen VI (Figures 1F and 1G), indicating that
while the FRC cellular network remained connected and intact,
the accompanying ECM components of the conduit remained
associated with the FRCs but were no longer replete.
CLEC-2 Binding Regulates ECM Production by FRCs
FRCs rapidly change their morphology and network architecture
in response to CLEC-2+ migratory DCs (Acton et al., 2014). We
hypothesized that the remodeling of the cellular network mayalso affect the remodeling of the associated ECM downstream
of the same DC/stromal contacts. We stimulated FRCs in vitro
with CLEC-2-Fc recombinant protein and compared transcrip-
tional profiles by RNA-seq (Figures 2 and S1). Bulk analysis of
the transcriptomic data comparing 6- and 24-h CLEC-2-Fc treat-
ment revealed that CLEC-2-Fc induced a transient and largely
reversible gene regulation response in FRCs (Figure S1A). This
transient transcriptional regulation follows kinetics similar to how
CLEC-2 inhibits PDPN-dependent contractility in FRCs (Acton
et al., 2014). Gene Ontology analysis (Mi et al., 2013, 2017)
showed that genes encoding proteins in the extracellular space/
region were most enriched among CLEC-2-Fc-regulated genes
(Figure 2A). Using the Matrisome database (Naba et al., 2012,
2016, 2017) of all ECM proteins and associated factors, we found
that FRCs expressed 570 of 743 matrisome genes in vitro, of
which 75 (13%, across all matrisome categories) were regulated
>2-fold 6 h after CLEC-2-Fc binding (Figures 2B and S1B).
FRCs regulated 35 core matrisome genes (>2-fold) in
response to CLEC-2-Fc, including 1 collagen (Col8a2), 23 glyco-
proteins, and 6 proteoglycans (Figure 2C). The downregulated
glycoproteins were mostly associated with cell-matrix adhesion
and migration, including Nov, Sparcl1, Ntn1, Igfbp5, Ndnf,
Spon2, Efemp1, and Fbln7 (de Vega et al., 2016; Ellis et al.,
2003; Gagliardi et al., 2017; Jia et al., 2005; Ohashi et al.,
2014; Song et al., 2011; Sureshbabu et al., 2012; Yin et al.,
2018). The glycoprotein genes induced had more pleiotropic
roles, such as growth factor signaling (Ctgf, Tsku, Wisp1, and
Ltbp2) (Enomoto et al., 2018; Lee et al., 2010; Niimori et al.,
2014; Ono et al., 2018) or immunomodulation (Spp1, Tnc, and
Crispld2) (Castello et al., 2017; Murdamoothoo et al., 2018;
Wang et al., 2009). The regulation of proteoglycan expression
by CLEC-2-Fc was more evident at 24 h, suggesting that
CLEC-2-Fc may be indirectly regulated (e.g., CTGF/CCN2 re-
presses Ogn, Dcn, and Omd; Seher et al., 2011). CLEC-2-Fc
increased the expression of Prg4, which inhibits synoviocyte
cell/matrix adhesion (Qadri et al., 2018).
Most of the 17 ECM-affiliated genes that were regulated by
CLEC-2-Fc were linked to cytoskeleton regulation (Afratis
et al., 2017; Casazza et al., 2007; Hamm et al., 2016) (Figure 2C),
including members of the semaphorin-plexin system, which pro-
vides guidance cues for migration (Casazza et al., 2007). Known
to inhibit axonal growth (Casazza et al., 2007), the expression of
Sema6c,Sema5a,Sema3f,Sema3e,Sema3a, andSema3dwere
reduced upon CLEC-2-Fc treatment, hinting that FRCs may
spread using similar mechanisms. Of note, CLEC-2-Fc induced
the expression of Sema7a, which represses ECM production in
other fibroblasts (Esnault et al., 2017).
CLEC-2-Fc regulation of 23 ECM regulators (Figure 2C) mainly
affected protease inhibitors, including the upregulation of
Serpine1, Timp1, and Timp3, key in the negative regulation of
matrix metalloproteinase (MMP) activity (Flevaris and Vaughan,
2017; Zhai et al., 2018). Also upregulated are Sulf1 and Tll1,
which are involved in ECM biogenesis (Kessler et al., 1996; Nag-
amine et al., 2012). CLEC-2-Fc repressed the expression of
several ECM regulator geneswith prominent roles in ECMdegra-
dation: Hyal1 (hyaluronidase-1) (Harada and Takahashi, 2007),
Agt (SERPINA8/angiotensinogen) (Rodrigues-Ferreira et al.,
2012), Htra3 (Bost et al., 1998; Tocharus et al., 2004), Adamts1Cell Reports 29, 2810–2822, November 26, 2019 2811
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Figure 1. Conduit Composition Changes dur-
ing LN Expansion
(A) Representative maximum z stack projection of
intact naive lymph node stained for collagen IV using
PACT. Scale bar, 100 mm.
(B) Representative transmission electron microscopy
of naive LNs. Scale bars, 5 mm.
(C) Representative cryosection of a naive LN. Tile scan
(top) and magnification (bottom). Dashed line in-
dicates T and B cell boundaries. Scale bars, 500 mm
(tile scan).
(D) Cryosections of the T cell area naive and inflamed
LNs immunized with IFA/OVA. Scale bars, 100 mm.
(E) Quantification of collagen IV in the PDPN+ network
within the T cell area. Each point represents the me-
dian gray intensity of region of interest, from 5 bio-
logical replicates. Error bars represent means and
SDs. ***p < 0.0005.
(F) Quantification of collagen I within the PDPN+
network. Each point represents the median gray in-
tensity of region of interest, from 3 biological
replicates. Error bars represent means and SDs.
**p < 0.005.
(G) Quantification of collagen VI within the PDPN+
network. Each point represents the median gray in-
tensity of region of interest, from 5 biological
replicates. Error bars represent means and SDs.
****p < 0.0001.
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Figure 2. Effects of CLEC-2 on ECM Pro-
duction by FRCs
(A) Gene Ontology analysis, genes regulated by
CLEC-2-Fc R2-fold. RNA-seq data from 4 bio-
logical replicates per condition.
(B) CLEC-2-Fc-regulated matrisomal gene cluster
in a principal-component analysis (PCA) space.
Arrows indicate time course.
(C) Heatmaps of matrisomal genes regulated
R2-fold by CLEC-2-Fc. Four biological replicates
for each condition are shown. Color-coding rep-
resents Z score; row average is indicated (right).
(D) Fibronectin (top) and collagen VI (bottom)
representative immunofluorescence staining of
in vitro FRC-derived matrices. Maximum z stack
projections; scale bars, 20 mm.
(E) Median gray intensity for ECM components.
Each dot represents a region of interest, combined
from 3 biological replicates. Error bars represent
means and SDs. *p < 0.05, **p < 0.005,
***p < 0.0005, one-way ANOVA, Tukey’s multiple
comparisons test.(Porter et al., 2005), Adamts5 (Evanko et al., 2012), Adamts7
(Riessen et al., 2001), Adamts9 (Yoshina et al., 2012), Adamts15
(Dancevic et al., 2013), Adam9 (Roychaudhuri et al., 2014), and
Mmp16 (Roth et al., 2017).Cell ReportsThese data indicate that FRCs can sub-
stantially alter their transcriptional profile
following CLEC-2 binding and that tran-
scriptional regulation may play an impor-
tant role in ECM remodeling and cell
matrix adhesion in FRCs. Furthermore,
the induction of protease inhibitors plus
the repression of proteases suggest that
the observed loss of ECM within the
conduit during LN expansion (Figure 1D)
is unlikely to be due to degradation by
FRCs. Furthermore, since we observed
that collagens (I, IV, and VI) are reduced
in vivo in inflamed LNs (Figure 1D) but
were not transcriptionally regulated by
CLEC-2, this transcriptional regulation
alone cannot fully explain the reduced
ECM observed (Figure 1D).
To investigate whether the CLEC-2/
PDPN signaling axis regulates ECM pro-
duction at the protein level, we undertook
a proteomic analysis of FRC-derived
matrices in vitro (Figure S2). We
generated CLEC-2-Fc-secreting FRCs
to allow constant CLEC-2 stimulation
and compared them to PDPN-depleted
FRCs (PDPN knockdown [KD]) (Acton
et al., 2014) and a control FRC cell line.
Mass spectrometry analysis detected a
similar number of proteins in all 3 FRC
cell lines, in which 96 proteins were matri-
somal proteins, with almost 90% overlapamong the samples (Figure S2A). PDPN depletion phenocopies
the loss of contractility induced by CLEC-2 binding (Acton et al.,
2014); in contrast, when comparing ECM protein production,
PDPN KD FRCs appeared qualitatively different from either29, 2810–2822, November 26, 2019 2813
Figure 3. Phosphoproteomics of CLEC-2-Fc-Treated FRCs
(A) Experimental setup, comparison of 5 control (untreated) and 5 CLEC-2-Fc-treated FRC cell lysates (biological replicates).
(B) Waterfall plots showing proteome regulation by CLEC-2-Fc.
(C) Control and CLEC-2-Fc-treated phosphoproteomes cluster in a PCA space.
(D) Volcano plots showing statistical regulation of the CLEC-2-Fc-treated FRC’s phosphoproteome (n = 5, two-tailed t test, Gaussian regression). The number of
regulated phosphosites is indicated.
(E) Empirical parent kinase analysis. The bars represent the number of targets for kinases. Positive and negative values indicate higher or lower phosphorylation in
CLEC-2-Fc-treated cells.
(F) Gene Ontology analysis for biological processes. Each bar represents a biological process significantly enriched by binomial analysis.control or CLEC-2-Fc-secreting FRCs (Figure S2B). PDPN KD
FRC-derived matrices showed an overall reduction in ECM com-
ponents, whereas CLEC-2-Fc-secreting FRCs and controls
were more closely aligned (Figure S2C). This suggests that the
loss of PDPN expression is not equivalent to CLEC-2modulation
of PDPN function in the case of matrix production.
While the CLEC-2/PDPN signaling axis influenced both matrix
transcription (Figures 2A–2C) and protein production (Figure S2),
how these changes translated to fibril formation, relevant to
conduit remodeling in vivo, was still unclear. Staining of decellu-
larized FRC-derived matrices for fibronectin and collagen VI
showed that ECM structures formed by CLEC-2-Fc-secreting
FRCs appeared disorganized compared to controls, with lower
alignment, large empty spaces, and lower median intensity of
matrix fibers (Figures 2D and 2E). In this functional assay,
PDPN KD FRCs phenocopied the effect of CLEC-2-Fc in matrix
deposition and organization. These experiments demonstrate
that CLEC-2/PDPN signaling regulates ECM remodeling at mul-
tiple levels, gene expression, protein production, and secretion
and fibril arrangement. These results also indicate that PDPN
expression by FRCs is a key requirement for FRCs to produce,
deposit, and align ECM components, and that this process is
modulated by CLEC-2.
Signaling Cascades Regulated by CLEC-2 in FRCs
The above results suggest that additional cellular mechanisms
are likely to regulate ECM deposition in FRCs. To address the
CLEC-2/PDPN-dependent signaling cascades controlling ECM2814 Cell Reports 29, 2810–2822, November 26, 2019organization, we performed an unbiased phosphoproteomics
analysis of FRCs by tandem mass tag mass spectrometry
(TMT-MS) (Tape et al., 2016) (Figure 3A). Control FRCs were
stimulated with CLEC-2-Fc for 15 min or 24 h to capture imme-
diate and late signaling responses. As expected, the total protein
levels did not differ significantly following treatment (Figure 3B).
However, phosphoproteome analysis revealed that CLEC-2-Fc
induced a rapid and transient signaling response in FRCs (Fig-
ure 3C). At 15 min, z400 phosphorylation sites were regulated
by CLEC-2-Fc (Figure 3D), corresponding to 77 proteins. In
contrast, after 24 h, only 8 phosphorylation sites corresponding
to 6 proteins were regulated compared to controls, confirming
the transient and reversible nature of responses to CLEC-2/
PDPN engagement (Figure 3D).
To elucidate signaling cascades regulated byCLEC-2, we per-
formed kinase target analysis (15 min dataset). We found that
CSNK2B and CDK1 regulated the highest number of predicted
targets (Figure 3E). Gene Ontology analysis of hits (Mi et al.,
2013, 2017) highlighted intracellular protein transport pathways
(Figure 3F) that were relevant to the transport and deposition
of cargo such as ECM components. However, using a GFP-
based assay, we found no reduction in protein secretion in either
CLEC-2-Fc-treated or PDPNKDFRCs (Figure S3). Nevertheless,
the impaired ECM deposition that was observed in both CLEC-
2-Fc-treated and PDPN KD FRCs (Figure 2D) prompted a closer
look at the phosphoproteomic data. Secretion of large cargo
proteins such as ECM components requires vesicle transport
via such cytoskeletal structures as the microtubule network
(Noordstra and Akhmanova, 2017). We found that several key
regulators of microtubule function were post-translationally
modified by CLEC-2-Fc stimulation, including cytoplasmic linker
protein 170 (CLIP-170), cytoplasmic dynein heavy chain 1, and
pleckstrin homology-like domain family B member 2 (LL5b).
While the direct function of these regulatory sites has not been
previously described, these data presented strong evidence
that CLEC-2 altered the organization of microtubules in FRCs,
a possible regulatory mechanism of ECM deposition in LNs.
CLEC-2 Binding Controls Microtubule Organization in
FRCs via LL5b
LL5b forms complexes that attach plus ends of microtubules to
the cell membrane, providing a secretory pathway for localized
exocytosis, which facilitates apicobasal cell polarity in epithelial
cells (Hotta et al., 2010; Lansbergen et al., 2006; Noordstra and
Akhmanova, 2017; Stehbens et al., 2014). Given that ECM com-
ponents in LNs are tightly compartmentalized by FRCswithin the
conduit, we reasoned that FRCs may be using a similar pathway
to secrete ECM. We therefore examined the role of LL5b in ECM
deposition by FRCs. We found that both CLEC-2-Fc treatment
and PDPN KD reduced LL5b protein and mRNA levels in
FRCs (Figures 4A and 4B). We attempted unsuccessfully to
overexpress a phosphomimetic mutant (LL5b S465E) in FRCs,
leading us to hypothesize that phosphorylation of LL5b at S465
may target LL5b for degradation.
Control FRCs clustered LL5b at the cell periphery (Figure 4C);
however, this accumulation was absent in PDPN KD FRCs and
more cytoplasmic in CLEC-2-Fc-treated cells (Figures 4C and
4D). The reduced peripheral localization of LL5b coincided with
the lower density of microtubules at the cell periphery in PDPN
KD and CLEC-2-Fc-treated cells (Figure 4E). We confirmed the
colocalization of LL5b with cortical microtubules in control
FRCs, in which LL5b+ areas presented a higher microtubule den-
sity compared to areas lacking LL5b (Figure 4F). To investigate
whether LL5b was required for microtubule attachment to the
cortex in FRCs, we silenced LL5b expression using small inter-
fering RNA (siRNA) (Figure 4G), which resulted in a correspond-
ing loss of microtubules from the periphery (Figure 4H). LL5b-si-
lenced FRCs also showed significantly reduced matrix
deposition (Figures 4I and 4J), phenocopying the disrupted ma-
trix generated following either CLEC-2-Fc treatment or PDPN
depletion (Figure 2H) and confirming that LL5b is necessary for
ECM deposition in FRCs.
Loss of FRC Adhesion and Reorganization of
Microtubule Networks
LL5b is recruited to mature focal adhesion complexes, which
require Rho-kinase (ROCK)/myosin-mediated contractility (Ka-
toh et al., 2001; Stehbens et al., 2014). Since the CLEC-2/
PDPN signaling axis inhibits actomyosin contractility in FRCs
(Acton et al., 2014), we predicted it may also alter FRC adhesion
to the underlying conduit and therefore inhibit the localization of
LL5b and microtubules to the cell cortex. We compared the
structure and localization of focal adhesions (p-paxillin) and
LL5b between FRC cell lines. In controls, LL5b clustered directly
adjacent to elongated mature focal adhesions (Stehbens et al.,
2014) (Figures 5A and 5B). However, CLEC-2-Fc-treated andPDPN KD cells presented significantly shorter focal adhesions
(Figures 5A and 5B). This was phenocopied by the direct inhibi-
tion of ROCK (Y-27632) (Figures 5A and 5B). This result shows
that when focal adhesion maturation is disrupted, there is a
concordant loss of LL5b clustering, linking actomyosin contrac-
tility, cell matrix adhesion, and LL5b recruitment in an integrated
mechanism (Figures 5A and 5B). To test these linked outcomes
in a more physiological assay, we stimulated FRCs with either
control or CD11cDCLEC-2 bone marrow-derived dendritic cells
(BMDCs). Cultured alone, FRCs displayed prominent F-actin
stress fibers and mature elongated focal adhesions to which
microtubule bundles docked in abundance (Figures 5C and
5D). Interaction with control (CLEC-2+) BMDCs induced the
loss of actin stress fibers, shorter focal adhesions, and lower
microtubule density at the periphery (Figures 5C and 5D). This
change in FRC morphology and function was not observed
with CD11cDCLEC-2 BMDCs (Figures 5C and 5D), demonstrating
that DC-induced inhibition of actomyosin contractility andmicro-
tubule localization requires CLEC-2.
We next asked whether LL5b directs the microtubule-medi-
ated deposition ofmatrix components in the FRCnetwork in vivo.
High-resolution imaging of LN tissue revealed that in naive LNs,
the entire FRC network expressed high levels of LL5b, and its
localization was always polarized inward toward the ensheathed
conduit (Figure 5E). In contrast, in inflamed LNs, we observed
many regions of the FRC network that lacked polarized localiza-
tion of LL5b, coincidingwith the loss of laminin in the same region
(Figure 5E). This is a direct translation of the in vitro studies that
predicted the loss of LL5bwhenmatrix adhesion is lost (Figures 4
and 5). These data require us to consider FRCs as polarized
cells, exhibiting apical and basolateral cell polarity similar to
epithelial sheets (Noordstra and Akhmanova, 2017), but enwrap-
ping the conduit similar to Schwann cells enwrapping nerve fi-
bers (Tricaud, 2018). The inner surface of the FRC adheres to
the conduit and recruits LL5b for ECM secretion, while the outer
surface of the FRC excludes ECM, allowing optimal interaction
with lymphocytes and antigen-presenting cells. Polarized and
localized exocytosis in FRCs, directed by LL5b, can mechanisti-
cally explain how ECM components are exclusively found within
the conduit and not elsewhere in the LN parenchyma.
Conduit Size Exclusion and Flow Persist during LN
Expansion
We next asked how remodeling the ECM would affect conduit
function. We compared the flow of fluorescently labeled dex-
trans through the LN sinuses and conduits of naive and acutely
inflamed LNs (5 days post-immunization). It has been previously
shown that 10-kDa dextrans can flow through the conduit, while
those >70 kDa are too large and are retained in the subcapsular
sinus (Gretz et al., 2000; Nolte et al., 2003; Roozendaal et al.,
2009; Sixt et al., 2005). In accordance with previous studies,
the 500 kDa dextran was excluded from all but themost proximal
branches of the conduit in both naive and inflamed LNs (Fig-
ure S4A), meaning that the filtering function and size exclusion
of the conduit network are maintained during LN expansion (Fig-
ure S4A). Furthermore, these results indicated that ECM loss
within the network did not impede the overall flow of small solu-
ble molecules through LNs.Cell Reports 29, 2810–2822, November 26, 2019 2815
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Figure 4. Regulation of Microtubule Organi-
zation by CLEC-2 via LL5b
(A) Representative western blots showing LL5b
expression in FRC cell lines.
(B) Expression of LL5b mRNA relative to control
FRCs by qPCR. Error bars represent means and
SDs of 2 biological replicates.
(C) Immunofluorescence of FRC cell lines in vitro.
Maximum z stack projections. Scale bars, 10 mm.
(D) Quantification of LL5b coverage in FRC cell
lines as a percentage of the total perimeter. Each
dot represents 1 cell. Error bars represent means
and SDs. ****p < 0.00005, one-way ANOVA,
Tukey’s multiple comparisons test.
(E) a-Tubulin intensity in the cortical area (10 mm
from the edge) of FRC cell lines. Each dot repre-
sents 1 cell. Error bars represent means and SDs.
****p < 0.00005, one-way ANOVA, Tukey’smultiple
comparisons test. NS, not significant.
(F) a-Tubulin intensity in the cortical area (10 mm
from the edge) in LL5b+ and negative areas in
control FRCs relative to the total area. Black dots
represent cells and blue dots represent cell areas.
Error bars represent means and SDs. *p < 0.05,
one-way ANOVA, Tukey’s multiple comparisons
test.
(G) Expression of LL5b mRNA by qPCR in LL5b
siRNA transfected FRCs (n = 2). Error bars repre-
sent means and SDs.
(H) aTubulin intensity in the cortical area (10 mm
from the edge). Each dot represents 1 cell.
Error bars represent means and SDs. **p < 0.005,
***p < 0.0005, one-way ANOVA, Tukey’s multiple
comparisons test.
(I) Representative in vitro cell-derived matrices
from LL5b KD FRCs, decellularized and stained for
fibronectin. Maximum z stack projections. Scale
bars, 100 mm.
(J) Median gray intensity for fibronectin staining.
Each dot represents a different region of interest,
from 2 biological replicates. Error bars represent
means and SDs.
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Figure 5. Focal Adhesion, Microtubule
Organization, and Contractility in FRCs
(A and B) Representative immunofluorescence of
FCR cell lines untreated and control FRCs treated
with Y-27632 ROCK inhibitor. (A) Maximum z stack
projections of representative images are shown.
Scale bars, 5 mm. (B) Quantification of FA length
from p-paxillin staining and LL5b coverage as a
percentage of the total perimeter. Dots represent
FAs (top) or single cells (bottom) from 2 biological
replicates. **p < 0.005, ****p < 0.00005, one-way
ANOVA, Tukey’s multiple comparisons test. Error
bars represent SDs.
(C) Immunofluorescence of FRC/DC cocultures
control or CD11cDCLEC-2 BMDCs. Maximum z
stack projections. Scale bars, 20 mm.
(D) Quantification of FA length and a-tubulin in-
tensity in the cortical area (10 mm from the edge).
Dots represent FAs (top) or single cells (bottom)
from 3 biological replicates. *p < 0.05, **p < 0.005,
****p < 0.00005, one-way ANOVA, Tukey’smultiple
comparisons test. NS, not significant. Error bars
represent SDs.
(E) Representative immunofluorescence of cry-
osections of naive and inflamed LNs immunized
with IFA/OVA.Maximum z stack projections. Scale
bars, 20 mm. Asterisks and arrowheads indicate
conduit-associated and conduit-independent
surfaces, respectively, of FRCs.
(F) Quantification of the indicated conduit com-
ponents within the PDPN network. Each dot rep-
resents the median gray intensity of a different
region of interest from 5 biological replicates.
Error bars represent means and SDs. *p < 0.05,
****p < 0.00005, unpaired t test.However, looking in more detail, we noticed the presence of
numerous gaps or interruptions in dextran flow (10 kDa) through in-
flamedLNs, inwhichonly<20%of theFRCsnetworkwasdextran+
in inflamedLNs (Figure6A, right panel).We found that thepresence
of dextran flow in inflamed LNs perfectly correlatedwith FRCs that
had maintained both polarized LL5b and laminin (Figure 6B), indi-
cating that conduit function is dysfunctional in many sections of
the FRC network. However, despite the substantial reduction in
conduit structuresduring acuteexpansion, theoverall global distri-
bution of small molecules through the conduit is maintained, rein-
forcing the robustness of the FRC network (Novkovic et al., 2016).
Conduit Sampling by CD11b+ Cells Is Increased in
Inflamed LNs
Solubleantigenflowthrough theconduit ensurescontrolledantigen
sensing by LN resident cells (Gretz et al., 2000; Nolte et al., 2003;
Palframan et al., 2001; Roozendaal et al., 2009; Sixt et al., 2005).Cell ReportsWe asked whether the interruptions in
conduit flow observed in inflamed LNs
would affect antigen uptake. Using flow
cytometry, we found a similar percent-
age of dextran+ cells in inflamed LNs
compared to naive (Figure 6C) within
90 min post-dextran injection. The total
number of dextran+ cells was approxi-mately doubled, but this is in line with the increase in LN cellu-
larity (Figure 6Di).We found increasednumbers of dextran+ cells
within bothMHC-II andMHC-II+ populations (Figure 6Dii), with
MHC-II+ cells representing 80% of all dextran+ cells (Fig-
ure S5B), themajority of these beingCD11c/lowCD11b+ (mono-
cytes/macrophages) cells in inflamed LNs (Figure 6Diii). Upon
examination of the tissue sections, we found that the increased
numbers of dextran+ monocytes/macrophages in inflamed LNs
may result from the active recruitment of more CD11b+ mono-
cytes/macrophages to conduits (Figure 6E). We observed dou-
ble the number ofCD11b+cells interactingwith the FRCnetwork
per area compared to naive controls (Figures 6E and 6F). Over-
all, we find that despite the local loss of conduit function (Fig-
ure 6A), the global robustness of the conduit network together
with the increasedmonocytes/macrophage recruitment to con-
duits is able to maintain soluble antigen uptake throughout LN
expansion.29, 2810–2822, November 26, 2019 2817
Naïve Naïve Inﬂamed
Inﬂamed
P
D
P
N
/1
0k
D
a
de
xt
ra
n
100
80
60
40
20
0
****
ns ns
*** **
***
**
Naïve Inﬂamed
%
d
e
xt
ra
n
+
a
re
a
N
a
ïv
e
Naïve Inﬂamed Conduit-interacting CD11b+ cells
In
ﬂa
m
e
d
In
ﬂa
m
e
d
(z
o
o
m
)
PDPN Laminin LL5β 10kDa dextranPDPN/Laminin/LL5β
*****
C
e
ll
co
u
n
ts
(x
1
0
5
)
C
e
ll
co
u
n
ts
(x
1
0
5
)
D
e
xt
+
ce
ll
co
u
n
ts
(x
1
0
5
)
%
D
e
xt
+
ce
lls
P
e
rc
e
n
ta
g
e
C
e
ll
co
u
n
ts
/2
0
0
m
ic
ro
n
2
Naïve Naïve
Naïve Naïve
Inﬂamed Inﬂamed
Inﬂamed Inﬂamed
Dext+
MHCII-
Dext+
MHCII+
CD11c+
CD11b+/-
CD11c-/low
CD11b+
Naïve
P
D
P
N
/L
am
in
in
/C
D
11
b
Naïve InﬂamedInﬂamed
A
B
DiC
E F 
ii iii
0.51
1
12
2
1.53
3
4
000
1
2
3
4
0 0
10
5
15
20
25
50
100
150
0
D
Figure 6. Conduit Flow and Antigen Uptake
in Inflamed LNs
Mice were immunized by the subcutaneous in-
jection of IFA/OVA on the right flank. Five days
later, fluorescently labeled 10 kDa dextran was
injected on both flanks.
(A) Immunofluorescence of 20-mm-thick cry-
osections of naive and inflamed draining LNs
30 min post-dextran injection. Maximum z stack
projections. Scale bars, 40 mm. Graph shows the
percentage of dextran+ areas within the PDPN+
network. Each dot represents a different region of
interest. Regions of interest are collated from 6
individual mice per group. Error bars represent
means and SDs. ****p < 0.0001, unpaired t test.
(B) Immunofluorescence of 20-mm-thick cry-
osections of naive and inflamed draining LNs
30 min post-dextran injection. Maximum z stack
projections. Scale bars, 20 mm. The asterisk in-
dicates a portion of the FRC network with all
conduit components plus dextran flow. The
arrowhead indicates a portion of the FRC network
in which the conduit is not present and dextrans
are not flowing.
(C) Percentage of dextran+ cells as quantified by
flow cytometry 90min after dextran injection. Error
bars represent means and SDs.
(D) The number of dextran+ cells per LN (i); the
number of MHCII+ dextran+ cells (ii); the number of
dextran+ cells within myeloid subsets (iii). Each dot
represents an individual mouse (n = 6). Error bars
represent means and SDs.
(E) Representative images of CD11b+ myeloid
cells in cryosections of the fibroblastic reticular
network. Scale bars, 20 mm.
(F) Quantification of the percentage (left) and the
number (right) of CD11b+ myeloid cells interacting
with conduit structures from regions of interest
from 5 biological replicates. Error bars represent
means and SDs.DISCUSSION
Our results show that conduit flow within the T cell area
conduit network is locally compromised during adaptive im-
mune responses and that ECM components are lost or effec-
tively diluted during early LN expansion. As a result, we
observe discontinuous conduit flow within inflamed LNs, indi-
cating areas of potential leakage. However, if conduits were
leaking soluble antigens, then we may expect increased indis-
criminate uptake by the many phagocytic cells within the tis-
sue. Instead, we see that dextrans continue to be sampled2818 Cell Reports 29, 2810–2822, November 26, 2019from the conduits by a subset of
myeloid cells and that an increased
number of CD11b+ monocytes/macro-
phages are recruited to interact with
the FRC network. We conclude that
the conduit network is sufficiently
robust in offering alternative routes
around the dysfunctional sections.
Conduit size exclusion requires plasma-lemma vesicle-associated protein (PLVAP) expression by the
lymphatic endothelial cells lining the sinus (Rantakari et al.,
2015). Our study provides further evidence that this barrier re-
mains intact during early LN expansion, continuing to protect
lymphoid tissue from intact pathogens.
Previous work has described the complex architecture of the
conduit network in the steady state, and it is known that FRCs
produce and organize ECM components (Malhotra et al., 2012;
Roozendaal et al., 2009; Sixt et al., 2005; Sobocinski et al.,
2010). We show that FRCs exhibit a type of apical/basolateral
cell polarity and organize microtubule networks to direct ECM
deposition unilaterally into conduit structures. Recruitment of
LL5b facilitates the docking and attachment of the plus ends of
microtubules to the cell membrane at sites of FRC-matrix adhe-
sion and enables matrix deposition.
We found that CLEC-2 binding to FRCs regulates their matrix
remodeling at both transcriptional and protein levels and also
regulates FRC adhesion, contractility, and microtuble networks
via LL5b recruitment, transiently inhibiting matrix deposition.
This mechanism would explain how LNs are able to avoid the
aberrant accumulation of excess ECM while enduring repeated
episodes of inflammation. We have previously shown that
CLEC-2+ DCs inhibit PDPN-dependent contractility in FRCs (Ac-
ton et al., 2014). This weakens FRC adhesion and in turn inhibits
the recruitment of LL5b to the conduit. LL5b expression is essen-
tial for FRCs to organize microtubules and form ECM matrices,
and it is exclusively localized basolaterally in FRCs in association
with laminin in vivo. We find that LL5b basolateral localization is
disrupted during LN expansion, which can account for the pro-
gressive loss of ECM during LN expansion.
Our results confirm that the FRC cellular network remains con-
nected in inflamed LNs (Acton et al., 2014; Astarita et al., 2015),
even though the conduit flow is locally disrupted. This also indi-
cates that FRC-FRC connectivity is prioritized over maintaining
ECMproduction. Our data suggest that to expand the LN rapidly,
FRCs detach temporarily from the conduit and halt matrix pro-
duction, leading to the local loss of conduit function as pre-exist-
ing ECMfibers are stretched through the expanding tissue. How-
ever, the remaining intact sections of conduit are sufficient to
channel the lymph throughout the LN parenchyma. Recent ob-
servations based on FRC ablation and a graph theory-based
systems biology approach have demonstrated that FRCs estab-
lish ‘‘small-world’’ networks (Novkovic et al., 2016; Textor et al.,
2016). High local connectivity ensures the high topological
robustness of the FRC network, which can tolerate the loss of
50% of all FRCs (Novkovic et al., 2016). We propose that a
similar principle applies to conduit flow, in which interruption of
the conduit network is efficiently overcome by sufficient alterna-
tive routes. These findings lead us to the question of how conduit
flow is determined, whether as a result of pressure from tissues
and afferent lymphatics pushing fluid through the conduit
network or, alternatively, whether the draw of fluid leaving the
system via high endothelial venules (HEVs) and efferent vessels
provides a pulling force. Since we find no evidence for leakiness
of conduits, which may be predicted in a model of pushing
forces, our data may suggest that flow is determined by pull
from the circulation. We cannot exclude that the dysfunctional
conduit flow that we observe in many sections of the FRC
network (Figure 6) is not due to a disruption or an alteration in
the drainage of tissue fluid such that conduits do not fill properly.
In contexts outside the LN, PDPN is often upregulated by fi-
broblasts in inflammatory settings (Hisakane et al., 2016; Kim
et al., 2015; Shindo et al., 2013). In these scenarios, the ECM
deposition by these fibroblasts could also be regulated and
modified by contact with CLEC-2+ myeloid cells or platelets
leaking from inflamed vessels. It will be interesting to understand
whether the same CLEC-2-dependent transcriptional and pro-
tein expression regulation occurs in other PDPN+ fibroblasts.
Since the CLEC-2/PDPN signaling axis also regulates FRCactomyosin contractility, this signaling pathwaymay also control
how ECM is aligned and organized in other tissues.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Experiments were performed in accordancewith national and institutional guidelines for animal care and approved by the Institutional
Animal Ethics Committee Review Board, Cancer Research UK and the UK Home Office. Wild-type C57BL/6J mice were purchased
from Charles River Laboratories. PDGFRaKI-H2BGFP mice (B6.129S4-Pdgfratm11(EGFP)Sor/J) were purchased from Jackson
Laboratories. Generation of CD11cDCLEC-2 was achieved as previously described (Acton et al., 2014) by crossing Clec1bfl/fl with
CD11c-Cre mice (B6.Cg-Tg(Itgax-cre)1.1Reiz). Both males and females were used for in vivo and in vitro experiments and were
aged 8–12 weeks. Cre-negative littermates were used as controls in all experiments.
Animal procedures
Immunisations
Mice were immunized via subcutaneous injection in the right flank of 100 mL of an emulsion of OVA in CFA or IFA (100 mg OVA per
mouse) (Hooke Laboratories). After 5 days, mice were culled and inguinal LNs from both flanks (naive and inflamed) were extracted
for paired histological studies or flow cytometry analysis.
Dextran uptake in vivo
Five days after immunization, mice were injected subcutaneously in both flanks with 20 mL of dextran solution (100 mg dextran
per flank) conjugated to: Cascade Blue (10kDa dextran), Tetramethylrhodamine (70 kDa dextran) or Fluorescein (500 kDa dextran),
all from Thermo Fisher Scientific. Mice were culled and paired inguinal LNs (inflamed versus non-inflamed) collected after 30 or
90 minutes for histological and flow cytometry analysis respectively.
Cell lines
In vitro experiments were performed using immortalized WT (control) and PDPN knockdown mouse FRC cell lines previously
described (Acton et al., 2014). For CLEC-2-Fc expression by FRCs, Clec1b cDNA was cloned into pFUSE-rIgG-Fc2 plasmids
(Invivogen) and transfected into WT FRCs using lipofectamine 2000 (Thermo Fisher Scientific). Transfected cells were selected by
prolonged culture with zeocin 100 mg/ml (Invivogen) and secretion of CLEC-2-Fc was confirmed by western blotting for cell-derived
supernatants (data not shown).
FRC cell lines were cultured in DMEMplus glutamax (Life Technologies, Invitrogen) supplemented with 10% FBS, Penicillin-Strep-
tomycin (100 U/mL) and 1% Insulin-Transferrin-Selenium (Life Technologies, Invitrogen) at 37C in 10% CO2. Cells were passaged
when they reached 80%–90% confluence, by incubating in Cell Dissociation Buffer (Thermo Fisher Scientific) for 10 minutes at 37C,
plus a gentle treatment of 1 min with Trypsin 0.25% (Thermo Fisher Scientific). When indicated, FRCs were treated with 50 mg/ml
CLEC-2-Fc or 10 mM ROCK inhibitor Y-27632 dihydrochloride (Tocris) for the last 2 hr of culture.
Primary cultures
Bone marrow cells were obtained from tibias and femurs from CD11cDCLEC-2 mice and Cre-negative control littermates. Whole bone
marrow was cultured in non-treated 10 cm Petri dishes in RPMI media supplemented with 10% FBS and Penicillin-Streptomycin
(100 U/mL) plus 20 ng/ml of recombinant murine GM-CSF (Peprotech) at 4x106 cells / 13 mL of medium. After 3 days, cultures
were supplemented with 4 mL of fresh media plus 37.2 ng/ml GM-CSF. After 6 days in culture, BMDCs were stimulated with
10 ng/ml Lipopolysaccharides from Escherichia coli 0111:B4 (Sigma-Aldrich) for 24 hr before harvesting.
METHOD DETAILS
Tissue clearing and immunostaining of intact LNs
We used a modified version of the PACT (passive clarity technique) for whole LN staining based on previous publication (Yang et al.,
2014). In brief, AntigenFix (DiaPath) fixed LNs were incubated overnight at 4C in 40% acrylamide + 25 mg/ml 2,20-Azobis(2-meth-
ylpropionamidine) dihydrochloride (Sigma). Infused samples were degassed with nitrogen for 5 min and then incubated for 6 hr at
37C. Samples were washed in PBS for 24 hr and incubated for 4 days with 8% SDS PBS solution at 37C. After washing with
PBS for 24 hr, LNs were incubated with 1:100 anti-collagen IV in PBS 2% goat serum (Abcam) 0.1% Triton X-100 (Sigma-Aldrich)
0.01% sodium azide (Webscientific) for 4 days at 37C (rotation). Same concentration of the antibody was added after 1 and
2 days. Then wash in PBS at 37C (rotation) for 24 hr and incubated with the secondary antibody in same conditions as the primary.
Samples were transferred to a 2 g/ml Histodenz (Sigma-Aldricht), 0.01% sodium azide solution in PBS, incubated for 24 hr and
imaged in this medium. Imaging was performed on a Leica TCS SP8 STED 3X using HC FLUOTAR L VISIR 25x water lenses.
Electron microscopy of LN conduits
LNs were fixed overnight in 2% PFA/1.5% glutaraldehyde (both EM grade from TAAB) in 0.1M sodium Cacodylate at 4C and
embedded in 2.8% low melting point agarose dissolved in PBS. Slices of 100 mm thickness were then cut in cold PBS using a
vibrating microtome (VT1200S; Leica) and returned to fresh fix solution for a further 15 mins. Slices were then secondarily fixed
for 1 h in 1%osmium tetraoxide/1.5% potassium ferricyanide at 4C and then treated with 1% tannic acid in 0.1M sodium cacodylate
for 45min at room temperature. Samples were then dehydrated in sequentially increasing concentration of ethanol solutions, and
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(UC7; Leica). Sections were collected on 13 2mm formvar-coated slot grids and stained with Reynolds lead citrate. All samples were
imaged using a transmission electron microscope (Tecnai T12; FEI) equipped with a charge-coupled device camera (SIS Morada;
Olympus).
Immunostaining of tissue sections
LN samples were fixed in AntigenFix (DiaPath) overnight, washed and incubated in PBS 30% sucrose (w/v) (Sigma-Aldrich) overnight
at 4C. Samples were embedded in Tissue-Tek O.C.T. Compound (Thomas Scientific) and frozen using 2-Methylbutane, cooled
with liquid nitrogen. 20 mm sections were cut using a Leica CM1850 cryostat. For immunostaining, tissue sections were blocked
for 2 hr at room temperature in 10% goat normal Serum (Sigma-Aldrich), 0.3% Triton X-100 (Sigma-Aldrich) in PBS. Primary anti-
bodies were incubated overnight at 4C in 10% goat normal Serum (Sigma-Aldrich), 0.01% Triton X-100 (Sigma-Aldrich) in PBS.
3 washing steps were used to remove unbound antibody, before incubation with the secondary antibody plus Hoechst (Fisher
Scientific) for 2 hr at room temperature. Samples were washed and mounted in mowiol. Samples were imaged on a Leica TCS
SP8 STED 3X using HC PL APO CS2 /1.4 63x oil lenses.
Image analysis
Conduit components
Podoplanin stainingwas used to define the FRC network in LN frozen tissue sections. Podoplanin signal was filtered byGaussian Blur
(sigma = 2) to remove background and thresholded identically in all samples. We next created a selection that was used in the
corresponding channels in order to obtain the median intensity of the conduit components. We performed this process in a number
of regions of interest within the T cell area for each LN, always minimizing the presence of vasculature.
Semiautomated quantification of focal adhesion length
Signal for phospho-Paxillin staining was thresholded equally in all samples after removal of background noise by Gaussian Blur
(sigma = 2). Focal adhesions were segmented using the analyze particle tool in Fiji and fit ellipse. Major axis of the ellipse was
used as an estimation of focal adhesion length.
RNaseq analysis
FRCs were cultured for 24h, adding 50 mg/ml of CLEC-2-Fc from then beginning or 6 hours before collecting cells. Cells were left
untreated as a control. RNA extractions were performed using the RNAeasy kit (QIAGEN) following the manufacturer’s instructions,
including a DNA digestion step to avoid genome contamination in further analysis.
For transcriptome sequencing and analysis, RNA preparations from FRCs were sequenced to a depth of 9 million to 22 million
reads by QueenMary University (QMUL) Genome Centre. The raw read quality control was performed by the QMUL Genome Centre
using BaseSpace Illumina software. Paired end FASTQ files were then aligned toMus musculusGRCm38 reference assembly using
STAR aligner software (Dobin et al., 2013). Transcripts were assembled and relative transcript abundance were calculated using
Salmon software (Patro et al., 2017). Using R (v3.4.4) and the Bioconductor tximport package (Soneson et al., 2015), TPM
(Transcripts per million) values were generated and annotated with ENSEMBL gene IDs. Bulk TPM data were categorised by the
fold change (> 2 fold) between control, 6 hr and 24 hr conditions using an in-house developed R script. Gene Ontology analysis
were performed using the PANTHER software (Mi et al., 2017; 2013) and PCA plots were generated using the ggplot package in R.
FRC-derived matrices
FRC-derived matrices were generated in vitro according to published methods (Franco-Barraza et al., 2016). In brief, gelatin-coated
wells were used to culture FRC cell lines at 5x103 cells/cm2 in culture media supplemented with 50 mg/ml L(+)-Ascorbic acid sodium
salt (Sigma-Aldrich) for 5 days, unless otherwise stated. Supplemented media was replenished at day 1 and 3. For proteomic anal-
ysis, cells in their matrix were collected in PBS, centrifuged and resuspended in 4M Urea. For microscopy analysis, cells were lysed
incubating for 15 min at 37C in PBS 1% Triton X-100 20 mM ammonium hydroxide. Matrices were blocked with 2% bovine serum
albumin (w/v) (Sigma-Aldrich) and stained with the indicated antibodies. Samples were imaged with a Leica TCS SP5 Confocal
Microscope using 63X oil HCX PL APO lenses.
Proteomics of FRC-derived matrices
Quantitative proteomic analysis of the FRC-derived matrices was performed by sequential window acquisition of all theoretical
spectra mass spectrometry (SWATH MS). For construction of the spectral library, FRCs and derived matrices were washed in
PBS, centrifuged and enriched for extracellular matrix as previously described in Krasny et al. (Krasny et al., 2018). Enrichedmatrices
were digested using gel-assisted protocol (Shevchenko et al., 2006) and desalted prior analysis by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) on Agilent 1260 HPLC coupled to TripleTOF 5600+ (SCIEX) mass spectrometer in data-dependent
acquisitionmode. For LC-MS/MS, peptides were spikedwith iRT peptides (Biognosys AG), loaded on a 75 mmx15 cm long analytical
column packedwith Reprosil Pur C18-AQ 3 mm resin (DrMaisch) end eluted using a linear gradient of 2%–40%of Buffer B (98%ACN,
0.1% FA) in 90 min at flow rate of 250nl/min. Acquired datasets were searched by ProteinPilot 5.0.1 software (Sciex) against a
Swissprot mouse database and spectral library was generated in Spectronaut 11 (Biognosys AG) from the results and combined
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8M Urea, 100mM ammonium bicarbonate buffer and digested using gel-assisted protocol. Desalted peptides were spiked with iRT
peptides and analyzed on the same LC-MS/MS instrument using identical LC conditions. MS/MS data were acquired in 60 SWATH
windows with fixed size of 13 Da. SWATH spectra were analyzed in Spectronaut 11 with FDR restricted to 1%. Further statistical
processing of median normalized data was performed in Perseus (1.5.6) 91.
Isobaric Tandem Mass Tag (TMT) Phosphoproteomics
Isobaric Tandem Mass Tag (TMT) Phosphoproteomics were performed as described in Tape et al. (2016) (PMID: 27087446).
Following treatment, FRCs were lysed in 6 M urea, 10 mM NaPPi, 20 mM HEPES, pH 8.0, sonicated, centrifuged to clear cell debris,
and protein concentration was determined by BCA (Pierce 23225). 200 mg of each condition were individually digested by FASP
(Wisniewski et al., 2009), amine-TMT-10-plex-labeled (Pierce 90111) on membrane (iFASP) (McDowell et al., 2013), eluted, pooled,
lyophilized, and subjected to automated phosphopeptide enrichment (APE) (Tape et al., 2014). Phosphopeptides were desalted us-
ing OLIGO R3 resin (Life Technologies 1-1339-03) and lyophilized prior to liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analysis. Samples were run on a Q-Exactive Plus mass spectrometer (Thermo Scientific) coupled to a Dionex Ultimate
3000 RSLC nano system (Thermo Scientific). Reversed-phase chromatographic separation was performed on a C18 PepMap 300 A
trap cartridge (0.3 mm i.d. x 5 mm, 5 mm bead size; loaded in a bi-directional manner), a 75 mm i.d. x 50 cm column (5 mm bead size)
using a 120 minute linear gradient of 0%–50% solvent B (MeCN 100% + 0.1% formic acid (FA)) against solvent A (H2O 100% + 0.1%
FA) with a flow rate of 300 nL/min. The mass spectrometer was operated in the data-dependent mode to automatically switch be-
tween Orbitrap MS and MS/MS acquisition. Survey full scan MS spectra (from m/z 400-2000) were acquired in the Orbitrap with a
resolution of 70,000 at m/z 400 and FT target value of 1x106 ions. The 20 most abundant ions were selected for fragmentation using
higher-energy collisional dissociation (HCD) and dynamically excluded for 30 s. Fragmented ions were scanned in the Orbitrap at a
resolution of 35,000 (TMT) at m/z 400. The isolation window was reduced to 1.2 m/z and a MS/MS fixed first mass of 120 m/z was
used to aid TMT detection. For accurate massmeasurement, the lockmass option was enabled using the polydimethylcyclosiloxane
ion (m/z 445.120025) as an internal calibrant. For peptide identification, raw data files produced in Xcalibur 2.1 (Thermo Scientific)
were processed in Proteome Discoverer 1.4 (Thermo Scientific) and searched against SwissProt mouse (2011_03 release,
15,082,690 entries) database using Mascot (v2.2). Searches were performed with a precursor mass tolerance set to 10 ppm, frag-
ment mass tolerance set to 0.05 Da and a maximum number of missed cleavages set to 2. Peptides were further filtered using a
mascot significance threshold < 0.05, a peptide ion Score > 20 and a FDR < 0.01 (evaluated by Percolator (Ka¨ll et al., 2007).
Phospho-site localization probabilities were calculated with phosphoRS 3.1 (> 75%, maximum 4-PTM/peptide) (Taus et al.,
2011). Phosphopeptides from Proteome Discoverer 1.4 were normalized against total protein levels (from in-gel digest experiments),
and protein-level phospho-site locations (phosphoRS 3.1 score > 75%, maximum 4-PTM/peptide) were manually annotated using
PhosphoSitePlus. Phosphoproteomic volcano plots display mean Proteome Discoverer 1.4 quantification fold-difference values
across all replicates (log2) against two-tailed t test P values (calculated from arrays of raw MS/MS TMT intensity counts). Volcano
plots were assembled in GraphPad Prism 6 (non-linear Gaussian regression, least-squares fit). For principle component analysis
(PCA), Proteome Discoverer 1.4 quantification ratio values were converted to log2, imported into R (version 3.0.1), computed using
the function ‘princomp(X)’ and plotted in GraphPad Prism. Empirical parent kinases were manually identified by referenced Uniprot
annotation and putative parent kinases were manually assigned using ScanSite (Obenauer et al., 2003) 3 (‘High- Stringency’ setting,
top 0.2% of all sites, lowest score). Phospho-sites that did not meet these conditions were not annotated.
GFP secretion assay
FRC cells lines were transfected with 500 ng of lumGFP plasmid (Blum et al., 2000) using Attractene Transfection Reagent (QIAGEN)
for 8 hr. Culture media was replenished with fresh media. After 15 hr, supernatants were collected and cells lysed in PBS 0.5% Triton
X-100. Supernatants were centrifuged in order to remove cell debris. GFP levels in cell lysates and supernatants were measured by a
solid-phase sandwich ELISA (Blagoveshchenskaya et al., 2002). Briefly, polystyrene 96-well plates were coated overnight with
200 ml/well of PBS plus sheep anti-GFP 1:50,000 for 1 hr at room temperature. The antibody solution was removed and the plates
were then incubated for 1 hr at room temperature to block nonspecific binding by using 300 ml/well of TEB (1% Triton X-100,
0.2% gelatin, 1 mM EDTA in PBS). The TEB was removed, each well was filled with 200 mL of samples or standard curve in TBE,
and the plates were incubated while shaking for 1 hr. After extensive washing, plates were incubated with 200 mL TBE plus Rabbit
anti-GFP 1:20,000 for 1 hr with shaking. Next, plates were washed and incubated with 200 ml/well of Goat anti-Rabbit HRP 1:3,000 in
TBE for 1 hr plus shaking. Plates were washed three times in TBE and 3 times in PBS and using a standard o-phenylenediamine
assay. Percentage of secreted GFP was calculated with respect to total GFP produced (supernatant plus lysates).
Western Blotting
Equal number of cells were seeded and cultured for 24 hours. Cells were washed with cold PBS and lysed using Laemmli buffer
(BioRad). All lysates were sonicated, heated for 10 min at 95C and treated with 143 mM b-mercaptoethanol. Electrophoresis gels
were loaded with the same quantity of lysates and run for 45 min at 130 V. Transfer to PDVF membranes were carried out at 65 V
for 2 hr. Membranes were blocked for 2 hr at room temperature with 5% skim milk powder (Sigma-Aldrich), 2% BSA in PBS and
stained with primary antibodies overnight at 4C in 1:5 diluted blocking buffer. The next day, membranes were thoroughly washed
in PBS 0.05% Tween 20 and incubated with HRP-conjugated secondary antibodies 1:5000 in 1:5 diluted blocking buffer.e4 Cell Reports 29, 2810–2822.e1–e5, November 26, 2019
Quantitative RT-PCR analysis for Phldb2 (LL5b) messenger RNA
cDNA was generated from RNA samples using the SuperScript IV Reverse Transcriptase kit (Thermo Fisher Scientific), following
manufacturer’s instructions. Quantitative PCRs were run using the MESA Blue qPCR Mastermix (SYBR Assay). We used specific
primers for detection of Phldb2 mRNA transcripts 1 and 2 (PrimerBank ID 23510303a1): Forward Primer AGCCGCGTTTC
TGAAAGCA (1653-1671); Reverse Primer CATCCGGGCGTCTTCCATT (1773-1755). Detection of GAPDH mRNA was used for
normalization.
Three-dimensional cell culture
FRCs were plated in 24-well MatTek plates at 3.5x103 cell/cm2. Matured BMDCs were harvested and 150,000 cells were seeded per
well in 150 ml collagen/matrigel matrix plus 20 ng/ml rmGM-CSF (Acton et al., 2012; Calvo et al., 2013; Gaggioli et al., 2007).
FRC:BMDC ratio 1:43. Gels were set at 37C for 30 min. After 24 hr, cells were fixed, permeabilized and stained for the stated cellular
components.
Immunostaining of cells in vitro
Cells were plated on 13 mm coverslips. Cells were fixed for 15 min in 3.6% formaldehyde and permeabilized with Triton X-100 0.3%
for 15min, at room temperature. Cells were blockedwith PBS 2%BSA for 1 hr at room temperature, followed by overnight incubation
with corresponding primary antibodies in PBS 1% BSA. After washing, cells were incubated with Alexa Fluor-conjugated secondary
antibodies plus Hoechst and/or phalloidin to reveal DNA in cell nuclei and F-actin respectively, all in PBS 1% BSA for 2 hr at room
temperature, washed and mounted on glass slides for imaging. Samples were imaged in Leica TCS SP5 and SP8 STED 3X Confocal
Microscopes using 63X HCX PL APO lenses or HC PL APO CS2 /1.4 63x oil lenses.
LL5b silencing by siRNA
WT FRC cell lines were transfected with four different siRNAs targeting LL5b expression (Dharmacon, GE Healthcare) using lipofect-
amine 2000 (Thermo Fisher Scientific). After 24 hr transfection, cells were washed and cultured in fresh media for an additional 12
hours before silencing efficiency was determined by qPCR. The following two siRNAs were selected for further assays: #1 GCAG
AGUAUCAGCGGAACA and #2 GAACAAUGAAGGACCGAGA. Scrambled RNA and non-template controls were used for
comparison.
Flow cytometry of LNs
Inguinal LNs were carefully dissected and digested using collagenase P at 200 mg/ml (Sigma-Aldrich), dispase II 800 mg/ml (thermos
fisher scientific) and DNase I 100 mg/ml (Sigma-Aldrich) in RPMI at 37C in a water bath. Every 10min LNs weremixed by pipetting up
and down and half of the digestion media replenished by fresh until all tissue was digested. Cell suspensions were centrifuged, re-
suspended in FACS buffer (PBS 2% FBS 10mM EDTA) and filtered through a 70 mm cell strainer (Corning). Cells were counted and
approximately 1x106 cells were used for immunofluorescence staining. In brief, cells were resuspended in 100 mL FACS buffer,
treated with Fc blocking for 10 min on ice and incubated with the indicated antibodies for 30 min on ice. Cells were washed exten-
sively and resuspended in 500 mL FACS buffer. Precision Count Beads (BioLegend) were used for accurate cell count. Samples were
run in a Fortessa X20 flow cytometer (BD Biosciences) at the UCL Cancer Institute and analyzed using the FlowJo software (FlowJo,
LLC). Live cells were gated by FSC/SSC parameters and doublets discriminated by comparing SSC-A versus SSC-H.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including the exact value of n, what n represents, precision measures (mean/median ± SD) and statistical
significance are reported in the Figures and Figure Legends.
Statistical analysis was performed using Prism 7 (GraphPad Software). For in vivo experiments, naive versus inflamed LNs were
compared by unpaired, parametric t test, assuming that both populations had the comparable standard deviation. For in vitro exper-
iments and all other multiple comparisons, ordinary one-way ANOVA followed by Tukey’s multiple comparisons test was performed.
Binomial test type for PANTHER Overrepresentation Test of cellular components (RNaseq) and biological process (Phosphopro-
teomics) was used to analyze changes induced by CLEC-2 binding to FRCs.
DATA AND CODE AVAILABILITY
RNaseq data and phospho-proteomics data are available: UCL research data repository: https://doi.org/10.5522/04/c.4696979;
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